DR RUGO: So the CREATE-X trial was a trial done in Japan and Korea, actually quite interesting. They gave patients who had residual disease after neoadjuvant therapy capecitabine at a high dose, higher than most Caucasian patients can tolerate, for 8 cycles. And they saw an improvement in disease-free survival and overall survival that was statistically significant. The difference was greater in patients with triple-negative disease than hormone receptor-positive disease. But overall, it was a significant finding.
This is quite intriguing. The trial took a very long time to accrue. And we haven’t seen the paper yet, right? It will be submitted, I think, sometime this year. What that data means, I think, is critical. Ingrid Mayer’s study that has 1 arm that’s CREATE-X-like will be helpful for us.
But I think that in practice, when you see a patient who has triple-negative disease who isn’t eligible for a trial and has residual disease after neoadjuvant chemotherapy, this is something that should be considered, because we otherwise don’t have ways of trying to improve their outcome. And their risk of recurrence and death is so extraordinarily high. I think it’s something that should be taken into account.
T, AC